EUVIMEDEUVIMED entdecken
Crossref

Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia

Finnian R Mc Causland, Brian L Claggett, Petr Jarolim, Martina M McGrath, Emmanuel A Burdmann, Kai-Uwe Eckardt, Andrew S Levey, John J V McMurray, Giuseppe Remuzzi, Ajay K Singh, Scott D Solomon, Robert D Toto und 1 weitere

American Journal of Nephrology · 2025

DOI: 10.1159/000549255 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Nephrology, 2025. Verfasst von Finnian R Mc Causland und 12 weiteren Autor:innen. Beteiligte Einrichtung: Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA, fmccausland@bwh.harvard.edu. Hauptthemen laut MEDLINE: Endothelin-1, Diabetes Mellitus, Type 2, Renal Insufficiency, Chronic, Anemia. Die Arbeit nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Endothelin-1 (ET-1) is a potent vasoconstrictor and is implicated in the pathogenesis of proteinuria and progressive chronic kidney disease (CKD). With the development of ET-1 receptor antagonists, there is interest in whether higher ET-1 concentrations are associated with a greater risk of adverse cardio-kidney events among high-risk patients, e.g., those with established CKD and type 2 diabetes mellitus (T2DM).

Methods

ET-1 concentrations were measured in a random subset of TREAT (n = 997 [25%] of the original 4,038 patients with CKD, T2DM, and anemia) using an automated ELISA assay on the Ella analyzer (ProteinSimple). We used unadjusted and adjusted Cox regression models to explore the association of baseline serum ET-1 (log-transformed and quartiles) with kidney events (composite of kidney failure or doubling of serum creatinine), heart failure (HF), and cardiovascular and all-cause death.

Results

At baseline, mean age was 67 ± 10 years and 56% were female. The mean eGFR was 34 ± 11 mL/min/1.73 m2; median urine protein/creatinine ratio was 0.4 (0.1, 1.7) g/g; median ET-1 was 2.4 (1.9, 3.0) pg/mL. During a median follow-up of 2.4 years, there were 225 kidney events, 99 HF events, 124 cardiovascular deaths, and 188 all-cause deaths. Each log-unit higher ET-1 was associated with a higher adjusted risk of the kidney composite (HR: 1.61; 95% CI: 1.08, 2.39), HF (HR: 2.61; 95% CI: 1.42, 4.81), but not with cardiovascular death (HR: 1.06; 95% CI: 0.65, 1.75) or all-cause death (HR: 1.33; 95% CI: 0.86, 2.04). Compared with the lowest quartile, categorical analyses suggested a higher risk of kidney events (HR 1.69; 95% CI 1.08, 2.64), HF events (HR: 2.35; 95% CI: 1.16, 4.80), and all-cause death (HR: 1.81; 95% CI: 1.09, 3.00) for the highest quartile of ET-1.

Conclusions

Among patients with established CKD, T2DM, and anemia, higher baseline ET-1 was associated with a higher subsequent risk of kidney outcomes, HF events, and all-cause death. Whether higher ET-1 predicts responsiveness to ET receptor antagonism warrants further investigation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endothelin-1Diabetes Mellitus, Type 2Renal Insufficiency, ChronicAnemiaHeart FailureCardiovascular DiseasesHumansFemaleAgedMaleMiddle AgedRisk FactorsCreatinineGlomerular Filtration Rate

Stichwörter der Autor:innen

Clinical trialsDeathEndothelinErythropoietinHeart failureOutcomes

Substanzen

Endothelin-1Creatinine

Autor:innen und Institutionen

  • Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA, fmccausland@bwh.harvard.edu.
  • Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.
  • Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Tufts Medical Center, Boston, Massachusetts, USA.
  • University of Glasgow, Glasgow, UK.

Zitieren

APA

Mc Causland, F. R., Claggett, B. L., Jarolim, P., McGrath, M. M., Burdmann, E. A., Eckardt, K. U., Levey, A. S., McMurray, J. J. V., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R. D., & Pfeffer, M. A. (2025). Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia. American Journal of Nephrology. https://doi.org/10.1159/000549255

Vancouver

Mc Causland FR, Claggett BL, Jarolim P, McGrath MM, Burdmann EA, Eckardt KU, et al. Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia. American Journal of Nephrology. 2025. doi:10.1159/000549255

BibTeX
@article{McCausland2025,
  author = {Mc Causland, Finnian R and Claggett, Brian L and Jarolim, Petr and McGrath, Martina M and Burdmann, Emmanuel A and Eckardt, Kai-Uwe and Levey, Andrew S and McMurray, John J V and Remuzzi, Giuseppe and Singh, Ajay K and Solomon, Scott D and Toto, Robert D and Pfeffer, Marc A},
  title = {Endothelin-1 and Cardio-Kidney Events among Patients with Chronic Kidney Disease, Diabetes, and Anemia},
  journal = {American Journal of Nephrology},
  year = {2025},
  doi = {10.1159/000549255}
}
Kostenlos starten →